|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
In comparison, GLP-1 RA appear to preferentially reduce ischemic events (stroke or myocardial infarction) over hospitalization for heart failure, and demonstrated renoprotection in several of the CVOTs.
|
31436559 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists on the other hand, showed significant reduction in MACE (RR 0.92; 95% CI 0.87-0.97), death from CV causes (RR=0.88; 95% CI 0.80-0.97), and death from any cause (RR=0.89; 95% CI 0.82-0.96).
|
30713085 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
This meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in major adverse CV events, CV death, stroke and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for heart failure.
|
31175007 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
GLP-1RA also reduced the risk of cardiovascular death by 12%, of non-fatal stroke by 16%, of hospitalization for heart failure by 9%, of all-cause mortality by 11%, and the broad composite kidney outcome by 17%; the latter appeared to be driven only by a reduction in macroalbuminuria (HR, 0.76 [0.68-0.86]; P = 0.003).
|
31373167 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP1-RA as a class reduce risk of ASCVD showing a significant reduction in MI and stroke.
|
30794833 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Fasting GLP-1 was higher in the patients that suffered a stroke compared to healthy controls (25.1 vs. 18.0 pmol/L; p = 0.004).
|
31307484 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An analysis of major adverse cardiovascular events (MACE) in the CVOTs shows that the CV benefits of GLP-1RAs are predominantly specific to atherosclerotic CV events (non-fatal myocardial infarction [MI], non-fatal stroke and CV death).
|
30957945 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess the cardiovascular efficacy of SGLT2 inhibitors or GLP-1RAs with regard to a three-point composite measure of major adverse cardiovascular events (non-fatal stroke, non-fatal myocardial infarction and cardiovascular mortality).
|
30653708 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, gliptins can also improve stroke outcome in rodents independently from GLP1.
|
29776406 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous research has demonstrated that GLP-1 analogs are neuroprotective in several neurological disease models including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke.
|
29705602 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Shortly thereafter, the injectable glucagon-like peptide agonists (GLP-1) liraglutide and semaglutide found a significant reduction in composite major cardiovascular events (CV death, non-fatal MI, or stroke).
|
30406850 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RAs significantly reduced infarct volume when administered acutely, but not later after stroke.
|
29411931 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2i and GLP-1 RA may have a synergic effect on glucose reduction, weight reduction, renal impairment (both an independent lethal disease and a CVD risk factor) improvement, and cardiac event reduction, because the first reduces HF and related events and the second decreases CVD risk (mainly MI and stroke).
|
29865997 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists did not affect the risk of MI (RR: 0.917; CI: 0.830-1.014; p = 0.092) as well as the risk of stroke (RR: 0.882; CI: 0.759-1.023; p = 0.097), HF (RR: 0.967; CI: 0.803-1.165; p = 0.725), retinopathy (RR: 1.000; CI: 0.807-1.238; p = 0.997) and nephropathy (RR: 0.866; CI: 0.625-1.199; p = 0.385).
|
29113708 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, semaglutide, a GLP-1 analog, has been shown to significantly reduce stroke incidence in a randomized controlled trial.
|
28477558 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
No trial evaluating GLP-1-analogues reported data on stroke, microvascular complications or socioeconomic effects.
|
28489279 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RA treatment was associated with a significant decrease in CVA, mortality, and the composite outcome in patients with and without established CVD, not significantly affecting AMI in these subgroups.
|
28407414 |
2017 |